We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ascap active surveillance
Previous Study | Return to List | Next Study

Active Surveillance for Cancer of the Prostate (ASCaP) (ASCaP)

This study is currently recruiting participants.
Verified August 2017 by Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
First Posted: July 30, 2009
Last Update Posted: August 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.

Condition Intervention
Prostate Cancer Other: Active surveillance

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.

Resource links provided by NLM:

Further study details as provided by Jonsson Comprehensive Cancer Center:

Primary Outcome Measures:
  • Discover and confirm clinical parameters that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables. [ Time Frame: Interim data analysis will be made every year ]

Secondary Outcome Measures:
  • Determine the clinical predictors of disease progression. Measure the recurrence-free, disease-specific, and overall survival of men on active surveillance for clinically localized prostate cancer. Determine factors that lead to active intervention [ Time Frame: Interim data analysis will be done each year ]

Biospecimen Retention:   Samples With DNA
Serum, plasma, buffy coat, prostate tissue cores and urine.

Estimated Enrollment: 462
Actual Study Start Date: June 4, 2009
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: June 4, 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
no treatment
Men with previously untreated, early stage prostate cancer.
Other: Active surveillance
Serial, long term data collection and active surveillance

Detailed Description:

This protocol is not designed as a formal clinical trial, but rather an observational protocol; no treatments and no randomization are included. Longitudinally, specimens and clinical data will be collected to provide information on the following:

  • Imaging studies of the prostate
  • Rates of curative intervention
  • Measures of tumor recurrence/progression
  • Disease specific survival
  • Overall survival
  • Clinical data to track Quality of Life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Community sample

Inclusion Criteria:

  1. Histologically confirmed adenocarcinoma of the prostate.
  2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
  3. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
  4. Patient has elected Active Surveillance as preferred management plan for prostate cancer.
  5. Patient consent has been obtained according to local Institutional Review Board .
  6. Patient is accessible and compliant for follow-up.

Exclusion Criteria:

  1. Unwillingness or inability to undergo serial prostate biopsy.
  2. Overall life expectancy less than 2 years
  3. Advanced prostate cancer
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00949819

Contact: Malu Macairan (310) 794-3566 mmacairan@mednet.ucla.edu
Contact: Leonard S Marks, M.D. (310) 794-3070 lmarks@mednet.ucla.edu

United States, California
University of California Los Angeles Recruiting
Los Angeles, California, United States, 90095
Principal Investigator: Leonard S Marks, M.D.         
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Principal Investigator: Leonard S Marks, M.D. University of California, Los Angeles
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00949819     History of Changes
Other Study ID Numbers: 11-002281
First Submitted: July 29, 2009
First Posted: July 30, 2009
Last Update Posted: August 28, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Jonsson Comprehensive Cancer Center:
Prostate Cancer
Low risk
Gleason 6
Active surveillance

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases